MedReleaf to collaborate with CFL Alumni Association in studying benefits of medical cannabis in managing chronic pain

MARKHAM, ON, May 24, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), today announced it will collaborate with the Canadian Football League Alumni Association ("CFLAA") in conducting an observational study on the benefits of medical cannabis in treating chronic pain and related ailments in retired professional athletes.  

MedReleaf and the CFLAA recognize the opportunity to collaborate on this important study which will bring greater awareness to the potential health benefits of using medical cannabis in the treatment of ailments that include chronic pain. The joint observational study is scheduled to begin in the summer of 2018 with volunteer CFLAA member participants.   

"We are excited to collaborate with the CFL Alumni Association on this significant observational study with legends in the Canadian athletic arena," said Neil Closner, MedReleaf CEO. "Through ongoing research, our understanding of the benefits of medical cannabis has grown significantly and we welcome the opportunity to apply our expertise in validating new patient therapies and contributing to positive patient outcomes for this exceptional group of former athletes."  

"The CFLAA has always sought to make a difference by providing support to our alumni, many of whom experienced medical challenges following their athletic careers," said Leo Ezerins, CFLAA Executive Director.  "In collaborating with MedReleaf we hope to gain further insight into the benefits of medical cannabis in managing chronic pain - insight that could be invaluable to our almost 2,000 alumni members."